BioScan AI Innovative Solutions delivers end-to-end AI-driven diagnostic solutions designed to detect and predict life-threatening diseases at their earliest stages. As India's first multiple disease prediction and detection company, BioScan AI combines proprietary hardware and software into integrated systems that produce results within minutes, making advanced diagnostics accessible in clinical and rural settings alike.

The company's flagship product, Drishti AI, uses artificial intelligence to analyze retinal images for the early detection of conditions including Glaucoma, Diabetic Macular Edema, Diabetic Retinopathy, Cardiovascular Diseases, Chronic Kidney Disease, and Alzheimer's. Paired with the Drishti Cam-01 hardware, the system generates detailed diagnostic reports in under 60 seconds and delivers them directly to the registered email address of the attending physician.

AutoThermix is BioScan AI's second major innovation, focused on the non-invasive early detection of breast cancer. Leveraging thermal imaging technology, AutoThermix analyzes breast tissue to identify potential signs of cancer at its earliest stages. The system follows a five-step workflow covering patient clinic visits, thermal scanning, image upload to a portal, automated diagnostics, and medical report generation. Its portable design makes it suitable for deployment in rural healthcare settings without requiring specialized infrastructure.

BioScan AI holds ISO 13485 certification and has FDA clearance pending for its devices. The platform is compatible with multiple camera models, features user-friendly interfaces requiring minimal training, and prioritizes both speed and data security throughout its diagnostic pipeline.